Release no 31/2010
Copenhagen and Oslo, 17th September, 2010
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
announced that the Danish Financial Supervisory Authority will report the
Company to the police for five occasions of violations of the flagging rules for
major shareholders possessions according to the Danish law on securities trading
article and for lack of announcements on capital raise in June and July 2009
according to article 6 of the declaration on share issuing.
The five occasions of violations of the flagging rules refer to one event; which
is the combination of Affitech AS and Pharmexa A/S in May 2009. The two article
6 violations also refer to the combination of the two companies and the
corresponding capital increase in July 2009.
In the consultative procedure Affitech A/S has stated that the Company
acknowledges that it has complied too late with formal obligations. The Company
has further stated that the information on the capital raise was public
information referring to announcements containing direct information on the
capital raise from June 19th 2009 (changed ownership), June 30th 2009
(prospectus) and August 25th 2009 (quarterly report) as well as later
announcements and the annual report of 2009. Affitech further issued a formal
release on the capital raise in 2009 in April 2010 as requested by the Danish
Financial Supervisory Authority.
--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
| Martin Welschof, Managing Director | Randi Krogsgaard, Corporate |
| | Communications |
| Tel # +47 95 12 81 37 | Tel # +45 2320 1001, e-mail: |
| | ir@affitech.com |
--------------------------------------------------------------------------------
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.
Affitech A/S to be reported to the police by the DSFA according to the Danish law on securities trading and article 6 in the declaration on issuers obligations to inform
| Source: Affitech A/S
Attachments
